Dr. Grazia Aleppo, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
676 N Saint Clair St Ste 701
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 248
Licensed in Illinois since 1999, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
IL license 036099550 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Palos Community Hospital Palos Heights, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 248
- Services billed
- 1,193
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 245 | 167 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 190 | 114 |
| Hemoglobin a1c level | 127 | 103 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 92 | 42 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 69 | 30 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 36 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 32 | 27 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 13 | 13 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chicago, IL | 202 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Chicago, IL | 199 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Chicago, IL | 127 |
| Ozempic (semaglutide) Other prescribers in Chicago, IL | 124 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Chicago, IL | 91 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in Chicago, IL | 89 |
| Mounjaro (tirzepatide) Other prescribers in Chicago, IL | 87 |
| Metformin Hcl Other prescribers in Chicago, IL | 84 |
| Jardiance (empagliflozin) Other prescribers in Chicago, IL | 78 |
| Atorvastatin Calcium Other prescribers in Chicago, IL | 76 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 28 payments worth $28,903 in total to this clinician.
| Dexcom, Inc. | $15,056 |
|---|---|
| Insulet Corporation | $10,104 |
| Eli Lilly and Company | $1,925 |
| Tandem Diabetes Care, Inc. | $1,500 |
| Medtronic, Inc. | $319 |
| Speaking at a medical education program | $14,357 |
|---|---|
| Consulting Fee | $6,753 |
| Compensation for services other than consulting (speaking, faculty) | $5,304 |
| Travel and Lodging | $2,000 |
| Food and Beverage | $490 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Dexcom, Inc. Feb 5, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $8,330 |
| Insulet Corporation May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Omnipod · Insulin Pump | $5,304 |
| Dexcom, Inc. Sep 23, 2025 | Speaking at a medical education program | $4,463 |
| Insulet Corporation Apr 9, 2025 | Consulting Fee OMNIPOD · Insulin Pump | $2,002 |
| Tandem Diabetes Care, Inc. Jun 12, 2025 | Consulting Fee t:slim X2 Insulin Pump with Control-IQ · Endocrinology Company’s descriptionConsulting Agreements File | $1,500 |
| Eli Lilly and Company Oct 6, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,375 |
| Insulet Corporation Oct 29, 2025 | Consulting Fee OMNIPOD · Insulin Pump | $1,326 |
| Dexcom, Inc. Sep 23, 2025 | Speaking at a medical education program | $595 |
| Eli Lilly and Company Aug 8, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $550 |
| Dexcom, Inc. Jul 22, 2025 | Speaking at a medical education program | $524 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Insulet Corporation Oct 29, 2025 | Consulting Fee OMNIPOD · Insulin Pump | $1,326 |
| Eli Lilly and Company Oct 6, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,375 |
| Dexcom, Inc. Sep 23, 2025 | Speaking at a medical education program | $4,463 |
| Dexcom, Inc. Sep 23, 2025 | Speaking at a medical education program | $595 |
| Eli Lilly and Company Aug 8, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $550 |
| Dexcom, Inc. Jul 22, 2025 | Speaking at a medical education program | $524 |
| Medtronic, Inc. Jun 21, 2025 | Travel and Lodging MINIMED 780G · Durable Pump · travel to Chicago, IL · in-kind | $12.42 |
| Tandem Diabetes Care, Inc. Jun 12, 2025 | Consulting Fee t:slim X2 Insulin Pump with Control-IQ · Endocrinology Company’s descriptionConsulting Agreements File | $1,500 |
| Insulet Corporation May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Omnipod · Insulin Pump | $5,304 |
| Insulet Corporation May 20, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $79.00 |
| Insulet Corporation May 20, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $24.57 |
| Insulet Corporation Apr 26, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $99.64 |
| Insulet Corporation Apr 25, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $439 |
| Insulet Corporation Apr 25, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $368 |
| Insulet Corporation Apr 25, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $249 |
| Insulet Corporation Apr 25, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $109 |
| Insulet Corporation Apr 9, 2025 | Consulting Fee OMNIPOD · Insulin Pump | $2,002 |
| Dexcom, Inc. Mar 7, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX · in-kind | $306 |
| Dexcom, Inc. Feb 25, 2025 | Speaking at a medical education program | $446 |
| Insulet Corporation Feb 24, 2025 | Travel and Lodging Omnipod · Insulin Pump · travel to Burlington, MA | $60.00 |
| Dexcom, Inc. Feb 5, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $8,330 |
| Dexcom, Inc. Feb 3, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX · in-kind | $179 |
| Dexcom, Inc. Jan 28, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX · in-kind | $75.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $288,479 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in part…
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care…
Bayer HealthCare Pharmaceuticals Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.